Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06181760




Registration number
NCT06181760
Ethics application status
Date submitted
25/10/2023
Date registered
26/12/2023

Titles & IDs
Public title
A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers
Scientific title
A Phase 1a, Randomized, Double-blind Placebo-controlled Study to Evaluate Safety and Tolerability and to Characterize the Pharmacokinetic Profile of Single Ascending Doses of Fenretinide Oral Capsules in Healthy Adult Volunteers
Secondary ID [1] 0 0
ISLA101-P01-CT001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Safety and Tolerability 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Fenretinide
Treatment: Drugs - Placebo

Active comparator: Fenretinide 300 mg/m2 - Single oral dose of fenretinide, 300 mg/m2

Active comparator: Fenretinide 600 mg/m2 - Single oral dose of fenretinide, 600 mg/m2

Active comparator: Fenretinide 900 mg/m2 - Single oral dose of fenretinide, 900 mg/m2

Placebo comparator: Placebo - Single oral dose of placebo capsules


Treatment: Drugs: Fenretinide
Ascending single doses of oral fenretinide

Treatment: Drugs: Placebo
Single oral dose of matching placebo capsules
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number and % of subjects experiencing adverse events following a single oral dose of fenretinide
Timepoint [1] 0 0
Day 1 to Day 8
Primary outcome [2] 0 0
Number and % of subjects experiencing serious adverse events following a single oral dose of fenretinide
Timepoint [2] 0 0
Day 1 to Day 8
Secondary outcome [1] 0 0
Assess the CMax - observed maximum plasma concentration following a single oral dose of fenretinide in the fasted state
Timepoint [1] 0 0
Day 1 to Day 8
Secondary outcome [2] 0 0
Assess the TMax - time to reach maximum concentration curve following a single oral dose of fenretinide in the fasted state
Timepoint [2] 0 0
Day 1 to Day 8
Secondary outcome [3] 0 0
Assess the AUC-8 Area under the concentration curve from zero to infinite time following a single oral dose of fenretinide in the fasted state
Timepoint [3] 0 0
Day 1 to Day 8
Secondary outcome [4] 0 0
Assess the AUC(last) - Area under the curve up to the last quantifiable timepoint after a single oral dose of fenretinide in the fasted state
Timepoint [4] 0 0
Day 1 to Day 8
Secondary outcome [5] 0 0
Assess the half life of a single oral dose of fenretinide in the fasted state
Timepoint [5] 0 0
Day 1 to Day 8

Eligibility
Key inclusion criteria
1. Healthy male or female volunteers not of childbearing potential, who are 18 years to 65 years of age (inclusive) at the time of signing the informed consent form (ICF).
2. Females not of childbearing potential, as defined in the following criteria:

1. History of hysterectomy.
2. Post-menopausal.

i. Natural post-menopausal females with at least 12 months from natural spontaneous amenorrhea and a serum follicle-stimulating hormone (FSH) concentration = 40 IU/L.

ii. Post-surgical females must have undergone bilateral oophorectomy at least 6 weeks prior to study.
3. Male subjects with female partners of childbearing potential must agree to practice abstinence or use a combination of 2 of the following acceptable birth control methods during the study and for at least 90 days after dosing:

1. Partners have an intrauterine device (IUD) without hormones in place for at least 3 months.
2. Barrier method (condom or diaphragm) for at least 14 days prior to screening and 90 days after dosing with study drug.
3. Partners using stable hormonal contraceptive for at least 3 months prior to screening and for 90 days after dosing with study drug.
4. History of vasectomy at least 3 months prior to signing the ICF.
4. Must be able to understand and provide signed informed consent for study participation.
5. Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
6. Body mass index (BMI) 18.0 to 32.0 kg/m2 (inclusive), and a body weight = 50 kg.
7. Normal renal function, defined as estimated glomerular filtration rate (eGFR) = 70 mL/min/1.73 m2 at screening and Day -1.
8. Clinical laboratory values should be within the laboratory's stated normal range. If not within this range, they must be without clinical significance, as determined by the Investigator.
9. No history of clinically relevant medical disorders, as determined by the Investigator.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Known or suspected pregnancy (confirmed via a positive serum human chorionic gonadotropin [hCG] pregnancy test at screening), planned pregnancy during the study period, nursing, or lactation.
2. Women of childbearing potential or men who intend to father a child or donate sperm during the study period and for 3 months after study drug administration.
3. Known allergy to fenretinide or any of the components of ISLA101.
4. Evidence or history of clinically significant medical conditions, such as hematological, renal, endocrine (e.g., polycystic ovarian syndrome or other anovulatory states), immunologic, pulmonary, metabolic, gastrointestinal (e.g., Crohn's disease, acute or chronic pancreatitis, and others) and surgery (except for simple appendectomy or repair of a hernia), which all can influence the absorption of study drug; cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing), or any other illness that the Investigator considers exclusionary or that could interfere with the interpretation of the study results.
5. History of severe infectious disease or recurrent infections.
6. Aspartate transaminase (AST), alanine aminotransferase (ALT), or total bilirubin above the 1.5 x upper limit of normal (ULN) at screening and Day -1.
7. Clinically significant electrocardiogram (ECG) abnormalities or vital sign abnormalities at screening and Day -1, long QT syndrome, or a history of cardiac disease.
8. Abnormal diet that may affect absorption, distribution, metabolism, or excretion of drugs, for example, lacking standard nutrients (e.g, cleansing diet 2 weeks before or during the study).
9. Positive result for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) at screening.
10. History of positive test for tuberculosis (TB) at screening.
11. A subject who has donated 1 unit of blood of over 500 mL within 56 days prior to the study drug administration, or donated plasma within 14 days prior to study drug administration.
12. Use of systemic antibiotics within 30 days prior to dosing.
13. Any use of drugs that inhibit or induce CYP enzymes within 30 days prior to administration of study drug and for the duration of study participation.
14. Use of any tobacco products, e-cigarettes, and/or nicotine replacement products in the 3 months preceding screening.
15. Any food allergy, intolerance, or restriction that, in the opinion of the Investigator, could contraindicate the subject's participation in this study.
16. Recent history of (within the past 12 months), or strong potential for, alcohol or substance abuse. Alcohol abuse will be defined as > 14 drinks per week (1 drink = 10g of ethanol).
17. History of drug or alcohol abuse within 5 years before screening or positive result of UDS (e.g, amphetamines, benzodiazepines, cannabinoids, cocaine, hallucinogens, opiates) or alcohol breath test at screening.
18. Exposure to any investigational agent or used an invasive investigational medical device within 30 days or within a period less than 5 drug half-lives prior to study entry (whichever is longer).
19. Study site employees, Sponsor's employees, or immediate family members of a study site or Sponsor employee.
20. Previously enrolled in this study.
21. Vaccination 14 days from screening or plans to get a vaccine within 30 days after dosing.
22. Acute infection (such as influenza) or relevant lesion at the time of Screening or Day -1. Subjects can be rescreened once they have recovered.
23. Criteria at the discretion of the Investigator:

1. Chronic medical condition that impacts subject safety.
2. Clinically significant abnormal physical examination or vital signs at screening.
3. Condition believed to interfere with the subject's ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the subject at undue risk.
4. History or evidence of a clinically significant disorder, condition, or disease that that is believed to significantly impair pain perception (e.g., history of stroke, history of neuropathy), would pose a risk to subject safety or interfere with evaluation, procedures, or study completion.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/11/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
13/02/2024
Sample size
Target
Accrual to date
Final
25
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Island Site 01 - Randwick
Recruitment postcode(s) [1] 0 0
2031 - Randwick

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Island Pharmaceuticals
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Beyond Drug Development
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Christopher Argent, MD
Address 0 0
Scientia Clinical Research
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06181760